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tency was observed in the out-of-pocket questionnaire(p  0.05). Component analysis 
showed a few epidemiological variables are responsible for 80% of instrument’s vari-
ability. CONCLUSIONS: Validated resource-use questionnaires are needed to homog-
enize costs and EE in developing countries. These validated questionnaires in Mexican 
population could be used by authorities to enhance cost-containment policies.
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The cost-effectiveness of health care interventions is often evaluated using quality-
adjusted life years (QALYs) as a measure of outcome. However, QALYs are valid only
under several restrictive assumptions. Furthermore, QALYs are ethically controversial,
as they receive their strongest support from utilitarian theory, which is often consid-
ered an unacceptable ethical theory. The purpose of this work is to present a non-
utilitarian approach to cost-effectiveness analysis, which avoids calculating QALYs, 
but still is able to aggregate and compare different clinical outcomes. By capturing 
beneﬁ ts in terms of adverse events (AEs) avoided, the approach is based on one of the 
fundamental metrics of clinical epidemiology and thus moves the assessment of cost-
effectiveness closer to that of clinical outcomes in clinical trials. Furthermore, it 
directly incorporates the two most important ethical values with regard to setting 
priorities in health care, ie, a concern for health gain as well as for health without
treatment. The approach aggregates the different types of AEs avoided, by introducing
weights that reﬂ ect their value. In order to project weights on an interval scale, ranking
data, the time trade-off, or the standard gamble method can be used.
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OBJECTIVES: Determining costs of concomitant medications (CONMEDs) is a chal-
lenging but critical component of cost-effectiveness analysis. In clinical trials,
CONMEDs are typically recorded using broad medication terms, with approximate 
costs linked to the entire category. In a recent phase III oncology clinical trial, we 
determined costs with an alternative approach based on the individual CONMEDs 
used by patients, using a combination of WHO preferred medication term codings, the 
NDC-HCPCS Crosswalk (CW), and Payment Allowance Limits (PAL) for Medicare
Drugs Part. METHODS: The CONMED database was obtained from the clinical trial, 
and the CW and the PAL were obtained from CMS. Preferred medication terms of 
individual CONMEDs were coded according to the WHODrug version 2003 Q2 dic-
tionary. The CW was used to map preferred medication terms to appropriate HCPCS
codes, and the PAL was used to determine unit costs of the HCPCS coded medications. 
For medications with multiple HCPCs codes, the average payment limit per dosage unit
was assigned. Total CONMED costs were computed by adding all cost information. 
RESULTS: The CONMED database comprised approximately 400 patients and 3,588
CONMED records. There were 562 unique HCPCS codes and 497 unique preferred
medication terms in the CW and the PAL. In addition, there were 519 unique combina-
tions of preferred medication terms and dose units, of which 78% (407/519) had mul-
tiple NDC codes. However, only 17% (70/407) of these had different unit payment
limits across products within the combination. In these cases the average cost was used. 
Overall we were able to assign costs to 22% (780/3588) of CONMED records, consis-
tent with the proportion of CONMEDs covered by Medicare. CONCLUSIONS: From 
third party payer perspective, this micro-costing method for CONMEDs was a feasible 
approach to pharmacoeconomic assessment with a clinical trial.
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OBJECTIVES: To evaluate an online freeware, cost-effectiveness calculator that gener-
ates and plots estimations related to the impact of medication compliance on life years
gained, drug expenditures, and total health care cost. METHODS: An online calcula-
tor and plotter were developed that estimates the impact of patient compliance on the 
cost-effectiveness of therapy. This model was based on a more complex compliance 
model description published by Hughes D. et al. The online data calculations were
compared with an MS Excel spreadsheet model. The cost effectiveness calculator is 
freely available through www.healthstrategy.com. Data inputs that can be modiﬁ ed 
include (for compliant and non-compliant separately): utility (QoL), annual drug
costs, annual non-drug costs, percent deaths per year, total number of study years, 
and number of initial patients. RESULTS: The online calculator runs on most personal
computer operating systems with javascript enabled browsers such as Internet
Explorer, Firefox, Opera, or Safari. For twenty different levels compliance (from 0 to
100 percent) this Internet tool outputs and plots results for: total QALYs, life years, 
total health care costs, non-drug expenditures and total health care expenditures. For 
100 patients over 5 years, the MS Excel spreadsheet data versus the online calculated 
values compared as follows for 50% compliance: QALYs (372 vs. 375), Life Years:(451
vs. 450), drug costs:($23,750 vs. $23,750), non-drug costs:($228,750 vs. $225,000), 
total health care costs:($252,500 vs. $248,750). CONCLUSIONS: With this online 
compliance and cost-effectiveness software, the user can enter their own data to cal-
culate and graph estimated QALYs, Life Years, drug costs, non-drug costs and total
health expenditures. This web-based calculator has potential beneﬁ t as a basic tool 
for students, health professionals, and decision-makers.
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OBJECTIVES: To evaluate an online, freeware calculator that generates and plots
sample size estimations and power analyses for cost effectiveness studies. METHODS:
Online software was developed and results were compared with a published analytical 
formula for power analysis and sample size calculations for cost and effectiveness data. 
The web-based, cost effectiveness calculator formulas, data and evaluation were based
on published articles by Briggs A, Gray AM and Tambour M. The online calculator 
required data inputs include: probability of Type I and Type II error, standard devia-
tion of costs and effects, mean cost and effect differences, correlation between differ-
ences in cost and effects, as well as willingness to pay (WTP) for additional health
effects. This Internet tool outputs results for sample size in each study arm that would
be required versus WTP threshold ranges, and power versus sample size. RESULTS:
Compared to the published manuscripts for a power of 0.90 and effectiveness only, 
the online calculated sample size results were identical (N  536). For the published 
examples with correlation differences in effect and cost of minus 1.0, the estimated 
sample sizes based on WTP compared as follows: WTP  $7500:(1400 vs 1387), WTP 
 $10,000:(1150 vs 1096), WTP  $15,000:(850 vs 865), WTP  $20,000:(790 vs 
769), WTP  $30,000:(700 vs 682). The Briggs et al articles include additional results
and sensitivity analyses based on additional correlations and power, which have to be
run one at a time with the online software. CONCLUSIONS: With this online freeware 
calculator, the user can enter their own data to estimate sample size and power in
planned or published cost effectiveness studies. This web-based software has potential
beneﬁ t as a basic tool for students, health professionals, and decision makers.
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OBJECTIVES: A major concern about the economic impact of preventive care
and medicines is that savings from avoiding morbidity may be more than offset 
by the costs of prolonging life, resulting in a net expenditure increase. The purpose
of this work is to examine this hypothesis. METHODS: A theoretical model is 
developed which determines the net outcome when savings from preventing morbidity 
are weighed against expenditures for added life years. The model is based on a single 
assumption, which is that costs and mortality are linearly correlated. This assumption 
holds for preventing the average disease because preventing all disease reduces 
mortality and costs by 100%. The model is validated based on long-term studies 
from the U.S. and Netherlands that model the economic impact of chronic-disease 
prevention. RESULTS: The model shows that for the average preventive measure 
savings from preventing morbidity are somewhat larger than expenditures in added 
life years. The ratio of savings to expenditures is approximately 1/(1 – relative reduc-
tion in all-cause mortality). The model is able to explain why some studies show 
that preventing chronic disease leads to savings while others do not. CONCLUSIONS:
This work provides new insight into the cost consequences of preventive care and
medicines. Results have implications for the economic evaluation of preventive 
medicines. For the average drug the long-term cost driver is not the additional life 
span, as expenditures during added life years roughly equal savings from morbidity 
reduction. Instead, increases in long-term costs are, on average, mainly driven by the 
medication itself.
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OBJECTIVES: To estimate the treatment effects of biologic disease modifying anti-
rheumatoid drugs (DMARDs) on quarterly total health care expenditure, while 
controlling endogeneity in treatment choice and allowing heterogeneity in treatment 
effects. The structural parameters, heterogeneous (ATE), and homogeneous (ATE1) 
average treatment effects were deﬁ ned as the impact of treatment on quarterly 
expenditure, if patients are randomly assigned to biologic DMARDs. METHODS:
Retrospective cohorts were constructed from California Medicaid paid claims between
January 1, 1999 to December 31, 2005. Non-overlapping quarters were created from 
pharmacy claims for biologic (adalimumab and etanercept) and standard (leﬂ uono-
mide, hydroxychloroquine and sulfasalazine) DMARDs. Final sample included 24504
episodes on 5510 patients. In the two-stage estimation, the treatment selection 
model was varied between multinomial and nested-logit, to avoid independence of 
irrelevant alternatives. The outcome equation was panel data ﬁ xed-effects correlated
random coefﬁ cients model (Wooldridge-2005), allowing heterogeneity in parameters.
